Increased expression of angiogenic genes in the brains of mouse Meg3-null embryos

Endocrinology

Volumn 151, Issue 6, 2010, Pages 2443-2452

  Gordon, Francesca E ^a   Nutt, Catherine L ^a   Cheunsuchon, Pornsuk ^a   Nakayama, Yuki ^a   Provencher, Katelyn A ^a   Rice, Kimberley A ^a   Zhou, Yunli ^a   Zhang, Xun ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; MATERNALLY EXPRESSED GENE 3; UNCLASSIFIED DRUG; CD31 ANTIGEN; GTL2 PROTEIN, MOUSE; PROTEIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN FUNCTION; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; GENE EXPRESSION; GENE FUNCTION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MICROARRAY ANALYSIS; MICROVASCULATURE; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; DNA MICROARRAY; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; PRENATAL DEVELOPMENT;

ANIMALS; ANTIGENS, CD31; BRAIN; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77954460345     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1151     Document Type: Article

References (56)

1. Asa SL, Ezzat S 2002 The pathogenesis of pituitary tumours. Nat Rev Cancer 2:836-849
2. Dekkers OM, Hammer S, de Keizer RJ, Roelfsema F, Schutte PJ, Smit JW, Romijn JA, Pereira AM 2007 The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 156:217-224
3. Dekkers OM, de Keizer RJ, Roelfsema F, Vd Klaauw AA, Honkoop PJ, van Dulken H, Smit JW, Romijn JA, Pereira AM 2007 Progressive improvement of impaired visual acuity during the first year after transsphenoidal surgery for non-functioning pituitary macroadenoma. Pituitary 10:61-65
4. Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S 2008 Medicaltherapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15:905-915
5. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A 2003 A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88:5119-5126
6. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Ansell PJ, Zhao J, Weng C, Klibanski A 2007 Activation of p53 by MEG3 non-coding RNA. J Biol Chem 282:24731-24742
7. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A 2005 Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression inhumanpituitary tumors. J Clin Endocrinol Metab 90:2179-2186
8. Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, Stratakis CA, Hedley-Whyte ET, Klibanski A 2008 Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 93:4119-4125
9. Astuti D, Latif F, Wagner K, Gentle D, Cooper WN, Catchpoole D, Grundy R, Ferguson-Smith AC, Maher ER 2005 Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer 92:1574-1580
10. Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M, Bourantas KL 2008 Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma 8:171-175
11. da Rocha ST, Tevendale M, Knowles E, Takada S, Watkins M, Ferguson-Smith AC 2007 Restricted co-expression of Dlk1 and the reciprocally imprinted non-coding RNA, Gtl2: implications for cisacting control. Dev Biol 306:810-823
12. McLaughlin D, Vidaki M, Renieri E, Karagogeos D 2006 Expression pattern of the maternally imprinted gene Gtl2 in the forebrain during embryonic development and adulthood. Gene Expr Patterns 6:394-399
13. Schuster-Gossler K, Bilinski P, Sado T, Ferguson-Smith A, Gossler A 1998 The mouse Gtl2 gene is differentially expressed during embryonic development, encodes multiple alternatively spliced transcripts, and may act as an RNA. Dev Dyn 212:214-228
14. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN 2003 Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602-1607
15. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM 1997 Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151:671-677
16. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C 2003 VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163-1177
17. Ferrara N, Gerber HP, LeCouter J 2003 The biology of VEGF and its receptors. Nat Med 9:669-676
18. Kanehisa M, Goto S 2000 KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27-30
19. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G 2000 Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 25:25-29
20. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ 2002 Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238-4244
21. Niveiro M, Aranda FI, Peiró G, Alenda C, Picó A 2005 Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol 36:1090-1095
22. Vieira JM, Schwarz Q, Ruhrberg C 2007 Selective requirements for NRP1 ligands during neurovascular patterning. Development 134:1833-1843
23. Oh H, Takagi H, Otani A, Koyama S, Kemmochi S, Uemura A, Honda Y 2002 Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA 99:383-388
24. Le Clainche C, Schlaepfer D, Ferrari A, Klingauf M, Grohmanova K, Veligodskiy A, Didry D, Le D, Egile C, Carlier MF, Kroschewski R 2007 IQGAP1 stimulates actin assembly through the N-WASPArp2/ 3 pathway. J Biol Chem 282:426-435
25. Hellström M,Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalén M, Gerhardt H, Betsholtz C 2007 Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445:776-780
26. Phng LK, Potente M, Leslie JD, Babbage J, Nyqvist D, Lobov I, Ondr JK, Rao S, Lang RA, Thurston G, Gerhardt H 2009 Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev Cell 16:70-82
27. Williams CK, Li JL, Murga M, Harris AL, Tosato G 2006 Upregulation of the Notch ligand Δ-like 4 inhibits VEGF-induced endothelial cell function. Blood 107:931-939
28. Imayoshi I, Shimogori T, Ohtsuka T, Kageyama R 2008 Hes genes and neurogenin regulate non-neural versus neural fate specification in the dorsal telencephalic midline. Development 135:2531-2541
29. Fischer A, Gessler M 2007 Δ-Notch-and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 35:4583-4596
30. Hatakeyama J, Bessho Y, Katoh K, Ookawara S, Fujioka M, Guillemot F, Kageyama R 2004 Hes genes regulate size, shape and histogenesis of the nervous system by control of the timing of neural stem cell differentiation. Development 131:5539-5550
31. Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino T, Ishino F 2000 Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells 5:211-220
32. Ottem EN, Godwin JG, Petersen SL 2002 Glutamatergic signaling through the N-methyl-D-aspartate receptor directly activates medial subpopulations of luteinizing hormone-releasing hormone (LHRH) neurons, but does not appear to mediate the effects of estradiol on LHRH gene expression. Endocrinology 143:4837-4845
33. Krsmanovic LZ, Mores N, Navarro CE, Tomić M, Catt KJ 2001 Regulation of Ca2+-sensitive adenylyl cyclase in gonadotropin-releasing hormone neurons. Mol Endocrinol 15:429-440
34. Himes AD, Raetzman LT 2009 Premature differentiation and aberrant movement of pituitary cells lacking both Hes1 and Prop1. Dev Biol 325:151-161
35. Kawaguchi A, Ikawa T, Kasukawa T, Ueda HR, Kurimoto K, Saitou M, Matsuzaki F 2008 Single-cell gene profiling defines differential progenitor subclasses in mammalian neurogenesis. Development 135:3113-3124
36. Wallez Y, Huber P 2008 Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta 1778:794-809
37. Phng LK, Gerhardt H 2009 Angiogenesis: a team effort coordinated by notch. Dev Cell 16:196-208
38. Mataraza JM, Briggs MW, Li Z, Entwistle A, Ridley AJ, Sacks DB 2003 IQGAP1 promotes cell motility and invasion. J Biol Chem 278:41237-41245
39. Le Boeuf F, Houle F, Huot J 2004 Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 279:39175-39185
40. Turner HE, Harris AL, Melmed S, Wass JA 2003 Angiogenesis in endocrine tumors. Endocr Rev 24:600-632
41. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT 1992 The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991
42. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR 1991 A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 88:9026-9030
43. Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K 2008 Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454:656-660
44. Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, Huot J 2000 Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 275:10661-10672
45. Lamalice L, Houle F, Jourdan G, Huot J 2004 Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 23:434-445
46. Yamaoka-Tojo M, Tojo T, Kim HW, Hilenski L, Patrushev NA, Zhang L, Fukai T, Ushio-Fukai M 2006 IQGAP1 mediates VE-cadherin-based cell-cell contacts and VEGF signaling at adherence junctions linked to angiogenesis. Arterioscler Thromb Vasc Biol 26:1991-1997
47. Fong GH, Rossant J, Gertsenstein M, Breitman ML 1995 Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70
48. Kappas NC, Zeng G, Chappell JC, Kearney JB, Hazarika S, Kallianos KG, Patterson C, Annex BH, Bautch VL 2008 The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 181:847-858
49. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nor JE 2010 VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 17:499-512
50. Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, Ferrara N 2000 A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. EMBO J 19:4064-4073
51. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH 1994 Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995
52. Pal S, Datta K, Mukhopadhyay D 2001 Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61:6952-6957
53. Sun D, Liu WJ, Guo K, Rusche JJ, Ebbinghaus S, Gokhale V, Hurley LH 2008 The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex- interactive agents. Mol Cancer Ther 7:880-889
54. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X 2009 Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res 15:492-501
55. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S, Albini A, Zauli G 2007 Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100:61-69
56. Honegger J, Zimmermann S, Psaras T, Petrick M, Mittelbronn M, Ernemann U, Reincke M, Dietz K 2008 Growth modelling of non-functioning pituitary adenomas in patients referred for surgery. Eur J Endocrinol 158:287-294